SELLAS Life Sciences announces additional positive TNBC subgroup data from phase 2b study
SELLAS Life Sciences announced additional data on patterns of clinical relapses (including site of recurrence), as well as results from a preplanned secondary efficacy analysis across various predefined subgroups from the prospective, randomized, single-blinded, controlled Phase 2b clinical trial. December 06, 2018
